相似文献
1
Correction of Psychoemotional Disorders and Short-Term Prognosis in Patients with COVID-19.
Neurosci Behav Physiol. 2022;52(9):1373-1378. doi: 10.1007/s11055-023-01369-w. Epub 2023 Feb 21.
2
[Correction of psychoemotional disorders and short-term prognosis in patients with COVID-19].
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(5):63-68. doi: 10.17116/jnevro202212205163.
3
[Features of psychoemotional status in patients with chronic thromboembolic pulmonary hypertension after cardiac surgery during the COVID-19 pandemic].
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(8):80-87. doi: 10.17116/jnevro202212208180.
4
[COVID-19 effect on mental health and sleep disorders].
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(4. Vyp. 2):49-54. doi: 10.17116/jnevro202112104249.
5
[Possibilities of complex non-drug programs in the correction of psychoemotional disorders of menopause in patients with metabolic syndrome].
Vopr Kurortol Fizioter Lech Fiz Kult. 2019;96(3):50-59. doi: 10.17116/kurort20199603150.
6
Pharmacogenetic Aspects of COVID-19 Management and Post-COVID-19 Depression Treatment with Fluvoxamine.
Psychiatr Danub. 2022 Sep;34(Suppl 8):25-30.
7
[Alpha-interferon and mental disorders].
Encephale. 2001 Jul-Aug;27(4):308-17.
8
[COVID-19 and stress-related disorders].
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(5. Vyp. 2):122-128. doi: 10.17116/jnevro2021121052122.
9
Psychosomatic Aspects of The Development of Comorbid Pathology: A Review.
Med J Islam Repub Iran. 2022 Dec 12;36:152. doi: 10.47176/mjiri.36.152. eCollection 2022.
10
[Postcovid cognitive impairment].
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(12):45-49. doi: 10.17116/jnevro202212212145.
本文引用的文献
1
Fluvoxamine for the treatment of COVID-19.
Lancet Glob Health. 2022 Mar;10(3):e329. doi: 10.1016/S2214-109X(21)00590-8.
2
Mechanisms of action of fluvoxamine for COVID-19: a historical review.
Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3. Epub 2022 Jan 7.
3
Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
JAMA Netw Open. 2021 Nov 1;4(11):e2136510. doi: 10.1001/jamanetworkopen.2021.36510.
4
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.
Br J Clin Pharmacol. 2022 May;88(5):2065-2073. doi: 10.1111/bcp.15126. Epub 2021 Dec 1.
5
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
6
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
7
[COVID-19 and stress-related disorders].
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(5. Vyp. 2):122-128. doi: 10.17116/jnevro2021121052122.
8
Sigmar1's Molecular, Cellular, and Biological Functions in Regulating Cellular Pathophysiology.
Front Physiol. 2021 Jul 7;12:705575. doi: 10.3389/fphys.2021.705575. eCollection 2021.
9
Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.
Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17.
10
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.
Front Pharmacol. 2021 Apr 20;12:652688. doi: 10.3389/fphar.2021.652688. eCollection 2021.
Zotero 插件